Cytax 260mg Injection

About Cytax 260mg Injection

Cytax 260mg Injection is an anticancer medication used in the treatment of several types of cancer, including breast cancer, non-small cell lung cancer, ovarian cancer, and AIDS-related Kaposi's sarcoma. It works by interfering with the growth and division of cancer cells, helping to slow or stop the progression of the disease. Cytax 260mg Injection may be administered alone or in combination with other chemotherapy medicines, depending on the type and stage of cancer being treated. This medication is not recommended for patients with severe liver impairment, uncontrolled infections, or significantly low white blood cell or platelet counts. It is also generally not recommended for children and adolescents under 18 years of age. Before starting treatment, patients should inform their healthcare provider about any history of heart disease or other underlying medical conditions. Cytax 260mg Injection may cause serious allergic reactions in some individuals and requires close medical supervision during administration. Patients of reproductive age should use effective contraception during treatment and for at least six months after the final dose to avoid pregnancy-related risks. As the formulation may contain alcohol, special caution is advised in individuals with alcoholism or conditions affected by alcohol exposure. Regular monitoring throughout treatment helps ensure the safe and effective use of Cytax 260mg Injection.

Key Features of Cytax 260mg Injection

Cytax 260mg is a chemotherapy agent that utilizes Paclitaxel to combat ovarian cancer. Designed for intravenous administration, it is supplied in single-use vials and is recognized for its proven efficacy in targeting malignant cells. Proper storage below 25C ensures the stability and potency of the medication. Produced in India, Cytax 260mg Injection aligns with international pharmaceutical standards for anti-cancer treatments.


Proper Handling and Storage

Healthcare facilities should always store Cytax 260mg Injection in cool conditions, not exceeding 25C. Strict adherence to these guidelines helps maintain its effectiveness until the expiration date in 2028. It must be managed and administered by qualified medical professionals to assure patient safety and optimal therapeutic benefit.